Answers are grounded in this paper and cite their sources.
During 3 weeks of the birch pollen season 1982, a double-blind study was carried out in which the new long acting H1-antagonist astemizole 10 mg daily was compared to clemastine 3 mg daily for efficacy and tolerance in 45 patients with seasonal allergic rhinitis. Evaluation criteria were daily symptom and fatigue scores, daily nasal peak flow measurements (PEFRn) and global evaluation of effect and fatigue at the end of the study. Global evaluation showed astemizole to be superior to clemastine. None of the astemizole-treated patients considered their treatment to be without effect whereas one third of the patients treated with clemastine considered the treatment ineffective. Although daily total symptom scores revealed no statistically significant difference between the two treatment groups, astemizole-treated patients experienced less nasal obstruction than did patients treated with clemastine, a difference that was also indicated by similar differences in DLPEFRn during the first 10 days of treatment. No severe side-effects were detected. The data point to a lower sedation profile of astemizole compared to clemastine.
No takes yet. Share an insight, caveat, or question.
Arve Bryhni Frostad (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: